EPHA2 and cancer: Two phase I trials were conducted in patients with advanced or metastatic EphA2-positive cancers to test safety, tolerability, pharmacokinetics, pharmacodynamics, and biodistribution of the anti-EphA2 mAb DS-8895a [92,93].